 Felipe Valenca Pereira
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma, Experimental | 6 | 2019 | 109 | 1.070 |
Why?
| | STAT3 Transcription Factor | 2 | 2021 | 205 | 0.850 |
Why?
| | Interleukin-6 | 2 | 2021 | 770 | 0.570 |
Why?
| | Cell Movement | 2 | 2021 | 959 | 0.550 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2019 | 168 | 0.500 |
Why?
| | Organometallic Compounds | 2 | 2019 | 113 | 0.430 |
Why?
| | Antineoplastic Agents | 6 | 2021 | 2201 | 0.410 |
Why?
| | Apoptosis | 4 | 2013 | 2397 | 0.390 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2021 | 175 | 0.360 |
Why?
| | Mitochondria | 4 | 2021 | 984 | 0.350 |
Why?
| | Mice, Inbred C57BL | 11 | 2021 | 5967 | 0.350 |
Why?
| | Mitochondrial Proteins | 3 | 2020 | 262 | 0.340 |
Why?
| | beta 2-Microglobulin | 1 | 2021 | 47 | 0.330 |
Why?
| | Interferon-gamma Release Tests | 1 | 2021 | 32 | 0.330 |
Why?
| | Adenovirus Vaccines | 1 | 2020 | 2 | 0.310 |
Why?
| | Melanoma | 2 | 2020 | 757 | 0.310 |
Why?
| | Antigens, Surface | 1 | 2020 | 155 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2021 | 1129 | 0.300 |
Why?
| | Tellurium | 1 | 2019 | 4 | 0.300 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 68 | 0.290 |
Why?
| | Mice | 14 | 2021 | 18261 | 0.280 |
Why?
| | Virus Diseases | 1 | 2021 | 218 | 0.280 |
Why?
| | Recombinant Fusion Proteins | 1 | 2021 | 667 | 0.270 |
Why?
| | Neoplasm Metastasis | 3 | 2014 | 691 | 0.250 |
Why?
| | Mesenteric Arteries | 1 | 2016 | 17 | 0.250 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 3523 | 0.250 |
Why?
| | Aldosterone | 1 | 2016 | 42 | 0.250 |
Why?
| | Galactosylceramides | 1 | 2016 | 27 | 0.240 |
Why?
| | Lymphocytes | 1 | 2018 | 379 | 0.240 |
Why?
| | Dendritic Cells | 1 | 2020 | 498 | 0.240 |
Why?
| | Lipid A | 1 | 2016 | 27 | 0.240 |
Why?
| | Animals | 17 | 2021 | 37948 | 0.230 |
Why?
| | Flagellin | 1 | 2014 | 19 | 0.210 |
Why?
| | Serratia | 1 | 2014 | 3 | 0.210 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2014 | 8 | 0.210 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 915 | 0.210 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.210 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 277 | 0.200 |
Why?
| | Antigens, Bacterial | 1 | 2014 | 127 | 0.200 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2021 | 26 | 0.200 |
Why?
| | Propylene Glycols | 1 | 2013 | 28 | 0.200 |
Why?
| | Sphingosine | 1 | 2013 | 45 | 0.190 |
Why?
| | Cancer Vaccines | 1 | 2014 | 160 | 0.190 |
Why?
| | Lung Neoplasms | 4 | 2014 | 2660 | 0.190 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 470 | 0.190 |
Why?
| | Glycoproteins | 1 | 2014 | 353 | 0.180 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 34 | 0.180 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 771 | 0.180 |
Why?
| | Immunoglobulin Variable Region | 1 | 2012 | 80 | 0.180 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2012 | 85 | 0.180 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 97 | 0.170 |
Why?
| | Anacardiaceae | 1 | 2011 | 4 | 0.170 |
Why?
| | Monoterpenes | 1 | 2011 | 16 | 0.170 |
Why?
| | Palladium | 1 | 2011 | 18 | 0.170 |
Why?
| | Peptide Fragments | 1 | 2014 | 691 | 0.160 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2021 | 118 | 0.160 |
Why?
| | Actins | 1 | 2012 | 421 | 0.150 |
Why?
| | Immunotherapy | 1 | 2014 | 662 | 0.150 |
Why?
| | HLA-A2 Antigen | 2 | 2021 | 35 | 0.140 |
Why?
| | Cytokines | 2 | 2021 | 2045 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 441 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 881 | 0.140 |
Why?
| | Molecular Chaperones | 1 | 2020 | 181 | 0.140 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 501 | 0.140 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 834 | 0.140 |
Why?
| | Flow Cytometry | 3 | 2019 | 1154 | 0.130 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 1124 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 265 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 454 | 0.130 |
Why?
| | Signal Transduction | 3 | 2021 | 5185 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 835 | 0.110 |
Why?
| | Mice, Knockout | 3 | 2019 | 3109 | 0.110 |
Why?
| | Calcium | 1 | 2021 | 1182 | 0.110 |
Why?
| | Mice, SCID | 2 | 2021 | 368 | 0.110 |
Why?
| | Caspase 1 | 2 | 2016 | 146 | 0.110 |
Why?
| | Diet, High-Fat | 2 | 2020 | 261 | 0.110 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 610 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2011 | 850 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2021 | 2037 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2021 | 2184 | 0.100 |
Why?
| | Cell Survival | 2 | 2019 | 1092 | 0.100 |
Why?
| | Male | 10 | 2021 | 72431 | 0.090 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 601 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2016 | 781 | 0.090 |
Why?
| | Caspase 3 | 2 | 2013 | 234 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1889 | 0.090 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2011 | 74 | 0.080 |
Why?
| | HIV Core Protein p24 | 1 | 2021 | 32 | 0.080 |
Why?
| | Mice, Obese | 1 | 2020 | 66 | 0.080 |
Why?
| | Thrombomodulin | 1 | 2020 | 15 | 0.080 |
Why?
| | Cathepsin L | 1 | 2019 | 9 | 0.070 |
Why?
| | Cathepsin B | 1 | 2019 | 16 | 0.070 |
Why?
| | Stereoisomerism | 1 | 2019 | 102 | 0.070 |
Why?
| | Th1 Cells | 1 | 2019 | 139 | 0.070 |
Why?
| | Th17 Cells | 1 | 2019 | 100 | 0.070 |
Why?
| | Leptin | 1 | 2020 | 247 | 0.070 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2019 | 106 | 0.070 |
Why?
| | Actin Cytoskeleton | 1 | 2019 | 103 | 0.070 |
Why?
| | Macrophages | 2 | 2016 | 1496 | 0.070 |
Why?
| | Cell Adhesion | 1 | 2019 | 452 | 0.060 |
Why?
| | Humans | 11 | 2021 | 144667 | 0.060 |
Why?
| | Nigericin | 1 | 2016 | 1 | 0.060 |
Why?
| | Plasmodium yoelii | 1 | 2016 | 7 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2016 | 129 | 0.060 |
Why?
| | WT1 Proteins | 1 | 2016 | 12 | 0.060 |
Why?
| | Protective Agents | 1 | 2016 | 42 | 0.060 |
Why?
| | Acetylcholine | 1 | 2016 | 208 | 0.060 |
Why?
| | Models, Immunological | 1 | 2016 | 100 | 0.060 |
Why?
| | Receptors, Interleukin-1 | 1 | 2016 | 211 | 0.060 |
Why?
| | Protozoan Proteins | 1 | 2016 | 94 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2016 | 293 | 0.060 |
Why?
| | Malaria | 1 | 2016 | 73 | 0.060 |
Why?
| | Drug Synergism | 1 | 2016 | 352 | 0.060 |
Why?
| | Bone Marrow Cells | 1 | 2016 | 321 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4539 | 0.060 |
Why?
| | Administration, Mucosal | 1 | 2014 | 2 | 0.050 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2014 | 9 | 0.050 |
Why?
| | Toll-Like Receptor 5 | 1 | 2014 | 18 | 0.050 |
Why?
| | Interleukin-1beta | 1 | 2016 | 390 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2014 | 93 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2014 | 198 | 0.050 |
Why?
| | Immunization | 1 | 2016 | 374 | 0.050 |
Why?
| | Cross Reactions | 1 | 2014 | 130 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 572 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2016 | 252 | 0.050 |
Why?
| | Immunologic Memory | 1 | 2016 | 366 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2014 | 117 | 0.050 |
Why?
| | Mice, Inbred BALB C | 1 | 2016 | 1251 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 339 | 0.050 |
Why?
| | Fingolimod Hydrochloride | 1 | 2013 | 39 | 0.050 |
Why?
| | DNA Primers | 1 | 2014 | 507 | 0.050 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 154 | 0.050 |
Why?
| | NF-kappa B | 1 | 2016 | 657 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2013 | 190 | 0.050 |
Why?
| | Female | 4 | 2021 | 78304 | 0.050 |
Why?
| | Caspase 8 | 1 | 2012 | 47 | 0.040 |
Why?
| | DNA Fragmentation | 1 | 2012 | 39 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2016 | 2136 | 0.040 |
Why?
| | Candida albicans | 1 | 2012 | 60 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2014 | 501 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2012 | 158 | 0.040 |
Why?
| | bcl-2-Associated X Protein | 1 | 2011 | 52 | 0.040 |
Why?
| | Drug Resistance, Multiple | 1 | 2021 | 25 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2019 | 2489 | 0.040 |
Why?
| | Mitochondrial Membranes | 1 | 2011 | 40 | 0.040 |
Why?
| | Fungal Proteins | 1 | 2012 | 145 | 0.040 |
Why?
| | Mitochondria, Liver | 1 | 2011 | 70 | 0.040 |
Why?
| | Cell Respiration | 1 | 2021 | 105 | 0.040 |
Why?
| | Blotting, Western | 1 | 2013 | 1161 | 0.040 |
Why?
| | Base Sequence | 1 | 2014 | 2177 | 0.040 |
Why?
| | Caspases | 1 | 2011 | 229 | 0.040 |
Why?
| | Biomimetic Materials | 1 | 2021 | 78 | 0.040 |
Why?
| | Peptides | 1 | 2016 | 989 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2011 | 449 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2020 | 119 | 0.040 |
Why?
| | Molecular Structure | 1 | 2011 | 495 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 172 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2011 | 762 | 0.040 |
Why?
| | Gene Expression | 1 | 2014 | 1476 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2021 | 1046 | 0.040 |
Why?
| | Sulfhydryl Compounds | 1 | 2011 | 188 | 0.040 |
Why?
| | Cisplatin | 1 | 2011 | 339 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 496 | 0.040 |
Why?
| | Hepatocytes | 1 | 2020 | 221 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2591 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 398 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2021 | 717 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 631 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1078 | 0.030 |
Why?
| | Nanoparticles | 1 | 2020 | 512 | 0.030 |
Why?
| | Rats | 1 | 2011 | 5570 | 0.020 |
Why?
| | Time Factors | 1 | 2013 | 7140 | 0.020 |
Why?
| | Lung | 1 | 2014 | 4089 | 0.020 |
Why?
| | Neoplasms | 1 | 2021 | 2873 | 0.010 |
Why?
| | Aged | 1 | 2020 | 25955 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 35971 | 0.010 |
Why?
| | Adult | 1 | 2020 | 40489 | 0.010 |
Why?
|
|
Valenca Pereira's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|